Search Results

You are looking at 21 - 30 of 69 items for :

  • "bisphosphonates" x
Clear All
Full access

Stacey W. MucCullough, David Blaisdell, Jonathan K. Kish, Pat Farmer, JaLyna Laney, Tom Valuck, Natalie Dickson, Johnetta Blakely, Dianna Shipley, Jesus Berdeja, Gregg Shepard, Bertrand M. Anz III, Carolyn Kelsey, Jack Taylor, Chadi Nabhan, Jeffrey F. Patton and Annette Powers

Background: There is 1 multiple myeloma (MM) quality metric available (treatment with bisphosphonates, developed by the American Society of Hematology) to evaluate the quality of cancer care delivered to improve patient experience and outcomes. As

Full access

Jason Hu, Armen G. Aprikian, Marie Vanhuyse and Alice Dragomir

: osteoporosis, diabetes, rheumatoid arthritis, hyperthyroidism, use of bisphosphonates, and long-term corticosteroid use (at least 6 months). The Charlson comorbidity score was modified (excluded PCa diagnosis) and also derived using diagnostic codes from the 18

Full access

Patient Across Borders and Cultures Curigliano Giuseppe MD, PhD 03 2010 8 8 3 3 277 277 278 278 0080277 10.6004/jnccn.2010.0019 Does Adjuvant Bisphosphonate in Early Breast Cancer Modify the Natural Course of the Disease? A Meta-Analysis of

Full access

1 2 2 215 215 221 221 10.6004/jnccn.2003.0020 Taxanes in the Adjuvant Treatment of Breast Cancer Trauth Donna MD Goldstein Lori J. MD 4 2003 1 1 2 2 222 222 231 231 10.6004/jnccn.2003.0021 The Role of Bisphosphonates in Breast

Full access

Rashmi Chugh

relatively lower dose of IFN for a shorter period. Overall, the preclinical and clinical data suggest that IFN may have some benefit as an adjuvant treatment in osteosarcoma; the current EURAMOS study is evaluating this hypothesis. Bisphosphonates

Full access

Shaji K. Kumar

patients with MM. The 2017 NCCN Guidelines recommend the following adjunctive treatment: Bisphosphonates for bone disease (with prior dental examination): monitor renal function and for osteonecrosis of the jaw. Hypercalcemia: treat with hydration

Full access

, MBA Laronga Christine MD Coyne Karen RN, CTR, MSc Hildreth Lynne MHA 02 2014 12 12 suppl_1 suppl_1 S-13 S-13 S-15 S-15 012S-13 10.6004/jnccn.2014.0206 Improving the Use of Intravenous Bisphosphonates in Women With Breast Cancer

Full access

Paul S. White, Michael Dennis, Eric A. Jones, Janice M. Weinberg and Shayna Sarosiek

Background Bone-modifying agents (BMAs) are an important component of supportive care for many patients with cancer. These agents include the intravenously administered bisphosphonates pamidronate and zoledronic acid, in addition to denosumab, a

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead and Rashmi Kumar

regional lymph nodes. A scar boost of 10 Gy, at 2 Gy per fraction, to a total dose of approximately 60 Gy may be considered in patients at increased risk for recurrence. Adjuvant Bisphosphonate Therapy The antiresorptive agents (bisphosphonates

Full access

Ronald S. Walters

sources required to review some of the data elements, such as order entry and administration (for the bisphosphonate measure), the OFI team felt this review should be performed by qualified physicians. This review required 30 to 45 minutes for each case